Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
This article was originally published in The Tan Sheet
Executive Summary
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)